Filing Flows › Celldex Therapeutics (CLDX) › Q1 2026
Celldex Therapeutics (CLDX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Celldex Therapeutics (CLDX) reported revenue of $15K for the first quarter 2026 (Q1 2026), -98% from a year earlier and -88% from the quarter before.
Celldex Therapeutics, Q1 2026: revenue $15K (-98% year over year), net loss $78.7M, operating cash flow −$65.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15K | -88% | -98% |
| Operating profit | −$84.4M | — | — |
| Net earnings | −$78.7M | — | — |
| Operating cash flow | −$65.6M | — | — |
What changed
Revenue was $15K in Q1 2026, down 98% year over year and down 88% from the previous quarter.
Operating costs exceeded revenue by $84.4M, an operating margin of -562900.0%. Total costs grew 33% against a revenue fall of 98%. The fastest-growing cost line was Research & development (+39%). The quarter ended with a net loss of $78.7M, narrower than the previous quarter's $81.3M loss.
Operating cash flow was −$65.6M. Non-cash charges added back $854K of depreciation and amortization and $8.5M of share-based compensation. Working capital and other items added $3.7M. Capital expenditures of $1.6M exceeded it, leaving free cash flow of −$67.2M.
Questions
What was Celldex Therapeutics' revenue in the first quarter 2026?
Celldex Therapeutics (CLDX) reported revenue of $15K for the first quarter 2026 (Q1 2026), -98% from a year earlier and -88% from the quarter before.